ATG4B

Across TCGA pan-cancer cohorts, ATG4B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATG4B data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATG4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG4B expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where ATG4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.192	0.466	.038	2	view →
LUAD	DFS	Tertile	II,III,IV	0.692	0.384	.033	2	view →
PDAC	DFS	Median	III,IV	0.452	0.255	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATG4B–GBM (DFS)

Open the GBM breakdown →